NR4A1 and neoplasm: Commonly investigated biomarkers in CMTs include hormone receptors such as oestrogen and progesterone receptors, which are used to assess tumour responsiveness to hormonal therapies, as well as human epidermal growth factor receptor 2, a receptor associated with more aggressive tumour behaviour.